AR and prostate carcinoma: Correspondingly, three anti-androgens clinically used for the treatment of prostate cancer, including bicalutamide, hydroxyflutamide and enzalutamide, showed similar inhibitory effects on the neoplastic transformation of MCA-SVHUC-AR cells [34].